drugset / Trial / NCT01639703

Hepatic Xenetix-CT Perfusion

NCT01639703

Phase 4 Completed 96 enrolled Guerbet
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.

Timeline

Start
2012-04
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Iobitridol Diagnostic / imaging agent 50 ml